Elanco Animal Health Incorporated

ELAN

US28414H1032

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			5-day change	1st Jan Change
13.31 ^USD	-1.11%		-0.75%	-10.67%

Apr. 01	Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board	MT
Apr. 01	Elanco appoints two directors after settling with activist Ancora	RE

Elanco Animal Health Incorporated Provides Earnings Guidance for the Fourth Quarter of 2022

November 08, 2022 at 06:30 am EST

Elanco Animal Health Incorporated provided earnings guidance for the fourth quarter of 2022. For the quarter, the company expects Revenue of $955 million to $1,000 million. Reported LPS of $0.12 to $0.07.

Latest news about Elanco Animal Health Incorporated

Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board	Apr. 01	MT
Elanco appoints two directors after settling with activist Ancora	Apr. 01	RE
Elanco appoints two directors to its board after agreement with Ancora	Apr. 01	RE
Elanco Animal Health Incorporated Appoints Kathy Turner and Craig Wallace, to Its Board of Directors	Apr. 01	CI
Elanco Animal Health Enters into Cooperation Agreement with Ancora Advisors	Apr. 01	CI
Activist investor Ancora secures two Elanco board seats, Bloomberg News reports	Mar. 31	RE
Transcript : Elanco Animal Health Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:05 PM	Mar. 12
Elanco Animal Health Insider Bought Shares Worth $322,808, According to a Recent SEC Filing	Mar. 08	MT
Transcript : Elanco Animal Health Incorporated Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM	Mar. 04
Elanco Animal Health Incorporated Appoints Shiv O'Neill as Executive Vice President, General Counsel and Corporate Secretary	Mar. 04	CI
Elanco Animal Health Incorporated Sends Communication to its Employees	Feb. 29	CI
Elanco Animal Health Incorporated Issues a Statement in Response to the Submission of Nominees by Ancora Holdings Group	Feb. 29	CI
Ancora seeks four board seats at Elanco amid push for changes	Feb. 29	RE
Elanco Animal Health Issues Response to Ancora Holdings' Board Nominations	Feb. 29	MT
Transcript : Elanco Animal Health Incorporated Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 02:10 PM	Feb. 29
Elanco Animal Health Shareholder Ancora Pushes for Board Refresh, Chief Executive Succession Plan	Feb. 29	MT
Ancora Nominates Candidates to Elanco Animal Health Board	Feb. 29	CI
Ancora seeks four board seats at Elanco amid push for changes, sources say	Feb. 29	RE
Morgan Stanley Adjusts Elanco Animal Health's Price Target to $17 From $16, Keeps Overweight Rating	Feb. 27	MT
Goldman Sachs Raises Price Target on Elanco Animal Health to $14 From $12.50, Maintains Sell Rating	Feb. 27	MT
Barclays Adjusts Price Target on Elanco Animal Health to $19 From $18, Maintains Overweight Rating	Feb. 27	MT
Sector Update: Health Care Stocks Mixed Premarket Monday	Feb. 26	MT
Transcript : Elanco Animal Health Incorporated, Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Elanco Animal Health's Q4 Adjusted Earnings Fall, Revenue Rises; 2024 Guidance Issued	Feb. 26	MT
Elanco Animal Health Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI

Chart Elanco Animal Health Incorporated

Duration

Period

More charts

Company Profile

Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Elanco Animal Health Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.46 USD

Average target price

17.24 USD

Spread / Average Target

+28.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
ELANCO ANIMAL HEALTH INCORPORATED	-10.67%	6.64B
BLUESTAR ADISSEO COMPANY	+16.00%	3.41B
VIRBAC	+0.14%	3.21B
VIMIAN GROUP AB	+2.53%	1.46B
JINYU BIO-TECHNOLOGY CO., LTD.	-14.67%	1.38B
VETOQUINOL SA	-2.44%	1.25B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-27.57%	1.21B
WUHAN KEQIAN BIOLOGY CO.,LTD	-12.86%	1.13B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-2.99%	1.03B
SWEDENCARE AB	-6.00%	843M

Veterinary Drugs